Y Intercept Hong Kong Ltd Makes New Investment in Novo Nordisk A/S (NYSE:NVO)

Y Intercept Hong Kong Ltd bought a new stake in Novo Nordisk A/S (NYSE:NVO) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 41,717 shares of the company’s stock, valued at approximately $4,967,000.

Several other hedge funds also recently modified their holdings of NVO. RFG Advisory LLC grew its stake in shares of Novo Nordisk A/S by 3.5% in the 2nd quarter. RFG Advisory LLC now owns 11,123 shares of the company’s stock worth $1,588,000 after acquiring an additional 381 shares in the last quarter. Park National Corp OH grew its position in Novo Nordisk A/S by 11.0% in the 2nd quarter. Park National Corp OH now owns 4,919 shares of the company’s stock worth $702,000 after purchasing an additional 487 shares in the last quarter. Dynamic Advisor Solutions LLC increased its stake in Novo Nordisk A/S by 21.3% in the 2nd quarter. Dynamic Advisor Solutions LLC now owns 28,049 shares of the company’s stock valued at $4,004,000 after buying an additional 4,927 shares during the last quarter. Sequoia Financial Advisors LLC lifted its position in shares of Novo Nordisk A/S by 4.6% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 31,829 shares of the company’s stock worth $4,543,000 after buying an additional 1,394 shares in the last quarter. Finally, Roman Butler Fullerton & Co. purchased a new position in shares of Novo Nordisk A/S in the 2nd quarter worth approximately $470,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Up 1.8 %

NVO opened at $110.77 on Monday. The firm has a market capitalization of $497.08 billion, a P/E ratio of 35.85, a price-to-earnings-growth ratio of 1.41 and a beta of 0.40. Novo Nordisk A/S has a one year low of $94.73 and a one year high of $148.15. The company has a fifty day moving average price of $111.31 and a 200-day moving average price of $127.07. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75.

Wall Street Analysts Forecast Growth

NVO has been the topic of a number of recent analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. BMO Capital Markets decreased their price objective on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. Finally, BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $150.40.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.